Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma
Journal of Clinical and Experimental Hematopathology · 2025
DOI: 10.3960/jslrt.25027 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2025. Verfasst von Kenichi Ito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 1, Pyrimidines, Gene Rearrangement, Lymphoma, B-Cell. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
- Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
Zitieren
APA
Ito, K., Hirano, K., & Sekiguchi, N. (2025). Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.25027
Vancouver
Ito K, Hirano K, Sekiguchi N. Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. 2025. doi:10.3960/jslrt.25027
BibTeX
@article{Ito2025,
author = {Ito, Kenichi and Hirano, Kazuhiko and Sekiguchi, Naohiro},
title = {Pemigatinib therapy in myeloid/lymphoid neoplasm with FGFR1 rearrangement manifesting as aggressive B-cell lymphoma},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2025},
doi = {10.3960/jslrt.25027}
}
EUVIMED